AN2 Therapeutics Initiates First-in-Human Clinical Trial for Potential Chagas Disease Cure, AN2-502998

Reuters

08/12

AN2 <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Initiates First-in-Human Clinical Trial for Potential Chagas Disease Cure, AN2-502998

AN2 Therapeutics Inc. has announced the commencement of its first-in-human clinical trial for the drug candidate AN2-502998, intended for the treatment of chronic Chagas disease. This Phase 1 trial aims to evaluate the safety, tolerability, and pharmacokinetics of the oral drug in healthy volunteers. Preclinical studies in nonhuman primates have indicated AN2-502998's potential to cure chronic Chagas disease. With no FDA-approved treatment available for adults with the disease, this development is significant. The company plans to complete Phase 1 dosing by the end of 2025. In collaboration with the Drugs for Neglected Diseases initiative, AN2 Therapeutics is also preparing for a Phase 2 trial, anticipated to start in 2026, with data expected in 2027. Results from the current Phase 1 trial have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250812650698) on August 12, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2558649905"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2558649905\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2558649905?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-12 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2558649905","market":"us","top_or_hot":-1,"title":"AN2 Therapeutics Initiates First-in-Human Clinical Trial for Potential Chagas Disease Cure, AN2-502998","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AN2 <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Initiates First-in-Human Clinical Trial for Potential Chagas Disease Cure, AN2-502998\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        AN2 Therapeutics Inc. has announced the commencement of its first-in-human clinical trial for the drug candidate AN2-502998, intended for the treatment of chronic Chagas disease. This Phase 1 trial aims to evaluate the safety, tolerability, and pharmacokinetics of the oral drug in healthy volunteers. Preclinical studies in nonhuman primates have indicated AN2-502998's potential to cure chronic Chagas disease. With no FDA-approved treatment available for adults with the disease, this development is significant. The company plans to complete Phase 1 dosing by the end of 2025. In collaboration with the Drugs for Neglected Diseases initiative, AN2 Therapeutics is also preparing for a Phase 2 trial, anticipated to start in 2026, with data expected in 2027. Results from the current Phase 1 trial have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250812650698) on August 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AN2 Therapeutics Initiates First-in-Human Clinical Trial for Potential Chagas Disease Cure, AN2-502998</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAN2 Therapeutics Initiates First-in-Human Clinical Trial for Potential Chagas Disease Cure, AN2-502998\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-12 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AN2 <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Initiates First-in-Human Clinical Trial for Potential Chagas Disease Cure, AN2-502998\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        AN2 Therapeutics Inc. has announced the commencement of its first-in-human clinical trial for the drug candidate AN2-502998, intended for the treatment of chronic Chagas disease. This Phase 1 trial aims to evaluate the safety, tolerability, and pharmacokinetics of the oral drug in healthy volunteers. Preclinical studies in nonhuman primates have indicated AN2-502998's potential to cure chronic Chagas disease. With no FDA-approved treatment available for adults with the disease, this development is significant. The company plans to complete Phase 1 dosing by the end of 2025. In collaboration with the Drugs for Neglected Diseases initiative, AN2 Therapeutics is also preparing for a Phase 2 trial, anticipated to start in 2026, with data expected in 2027. Results from the current Phase 1 trial have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250812650698) on August 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDLzTl8w:1","article_id":"2558649905","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2558649905","pubTimestamp":1754996489,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"AN2 Therapeutics Inc. has announced the commencement of its first-in-human clinical trial for the drug candidate AN2-502998, intended for the treatment of chronic Chagas disease. This Phase 1 trial aims to evaluate the safety, tolerability, and pharmacokinetics of the oral drug in healthy volunteers. Preclinical studies in nonhuman primates have indicated AN2-502998's potential to cure chronic Chagas disease. With no FDA-approved treatment available for adults with the disease, this development is significant. The company plans to complete Phase 1 dosing by the end of 2025. In collaboration with the Drugs for Neglected Diseases initiative, AN2 Therapeutics is also preparing for a Phase 2 trial, anticipated to start in 2026, with data expected in 2027. Results from the current Phase 1 trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, th","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ANTX":"AN2 Therapeutics, Inc."},"translate_title":"AN2 Therapeutics启动首个潜在治疗恰加斯病的人体临床试验AN2-502998","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANTX":0.9},"content_text":"AN2 Therapeutics Initiates First-in-Human Clinical Trial for Potential Chagas Disease Cure, AN2-502998\n    \n\n        AN2 Therapeutics Inc. has announced the commencement of its first-in-human clinical trial for the drug candidate AN2-502998, intended for the treatment of chronic Chagas disease. This Phase 1 trial aims to evaluate the safety, tolerability, and pharmacokinetics of the oral drug in healthy volunteers. Preclinical studies in nonhuman primates have indicated AN2-502998's potential to cure chronic Chagas disease. With no FDA-approved treatment available for adults with the disease, this development is significant. The company plans to complete Phase 1 dosing by the end of 2025. In collaboration with the Drugs for Neglected Diseases initiative, AN2 Therapeutics is also preparing for a Phase 2 trial, anticipated to start in 2026, with data expected in 2027. Results from the current Phase 1 trial have not yet been presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250812650698) on August 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}